IC
ACAD icon

Ikarian Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Ikarian Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-150,000
Closed -$6.34M – 166
2020
Q1 		$6.34M Buy
+150,000
New +$6.18M 0.48% 53

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ikarian Capital's ACAD Position: Q1 2026 in Review

Ikarian Capital opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 28,099 shares worth $625K. The stake represents 0.05% of the portfolio and ranks #122 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in ACAD as recently as Q1 2023.

Ikarian Capital first reported a position in ACAD in Q2 2020 and has held it in 12 quarters since. The position peaked at $5.32M in Q3 2022. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Ikarian Capital held 28,099 shares of Acadia Pharmaceuticals worth $625K as of Q1 2026.
  • Acadia Pharmaceuticals was a new Ikarian Capital position in Q1 2026.
  • Acadia Pharmaceuticals made up 0.05% of Ikarian Capital's portfolio in Q1 2026, its #122 holding.
  • Ikarian Capital first reported a position in Acadia Pharmaceuticals in Q2 2020 and has held it in 12 quarters since.
  • Ikarian Capital's Acadia Pharmaceuticals position peaked at $5.32M in Q3 2022.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.